drugset / Trial / NCT03903718

Evaluation of the Safety and Efficacy of a Monoclonal Antibody to Treat Influenza

NCT03903718

Phase 2 Withdrawn MedImmune LLC
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to evaluate the efficacy and safety of MEDI8852 for the treatment of influenza caused by a wild type A/H1N1 challenge strain in healthy, influenza serosusceptible adults.

Timeline

Start
2020-04-03
Primary completion
2020-10-09
Completion
2020-10-09

Drugs

EvaluationDrugModalityDoseRoute
Subject MEDI8852 Monoclonal antibody Intravenous
Subject Oseltamivir Small molecule 75 mg Oral

Indications